依达拉奉治疗急性脑梗死合并糖尿病的疗效研究

目的对照观察依达拉奉治疗急性脑梗死合并糖尿病患者的临床疗效及安全性。方法选取急性脑梗死合并糖尿病患者80例,随机分成两组,治疗组用依达拉奉注射液30mg加0.9%氯化钠溶液100ml静脉滴注,2次/d,共14d;对照组不用依达拉奉,其余治疗两组相同。两组基础用药相同：丹参注射液＋拜阿司匹林片。结果治疗第14天,治疗组ESS、MBI评分分别为（73.8±15.9）分、（56.2±26.8）分;对照组ESS、MBI评分分别为（61.4±18.1）分、（47.1±28.9）分,两组比较有显著性差异。治疗组有2例出现肾功能损害,停药后肾功能恢复正常,治疗组、对照组各有1例脑梗死灶内少量出血,不良反应两组比较无显著性差异。结论依达拉奉治疗急性脑梗死合并糖尿病患者安全有效,但原有肾病者使用时需慎重。

Edaravone Treatment of Acute Cerebral Infarction with Diabetes Efficacy

Objective Controlled study of edaravone for acute cerebral infarction patients with diabetes mellitus the clinical efficacy and safety.Methods Selected patients with diabetes mellitus with acute cerebral infarction,80 cases were randomly divided into 2 groups,treatment group edaravone injection 30mg 100ml normal saline infusion,2 times / d,a total of 14d;the control group without edaravone,and the remaining treatment between groups.The same two groups based on medication:Danshen injection+Aspirin tablets.Results Treatment after 14d,the treatment group ESS,MBI scores were 73.8±15.9,56.2±26.8;control group ESS,MBI scores were 61.4±18.1,47.1±28.9,compared the two groups was significant difference.Treatment group,2 patients had renal dysfunction,renal function returned to normal after stopping the treatment group and control group 1 case each of cerebral infarction in a small amount of bleeding,adverse reactions showed no significant difference.Conclusion Edaravone for acute cerebral infarction patients with diabetes mellitus is safe and effective,but is required to use the original kidney disease carefully.